Search results
Showing 251 to 300 of 8183 results
An independent advisory committee is responsible for making our interventional procedures recommendations. The committee includes both health...
NICE is unable to make a recommendation on decitabine–cedazuridine (Inaqovi) for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable. This is because Otsuka Pharmaceuticals (UK) did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA932
Evidence-based recommendations on percutaneous transarterial carotid artery stent placement for asymptomatic extracranial carotid stenosis. This involves using a wire mesh tube called a stent to widen the narrowed carotid artery.
View recommendations for IPG777Show all sections
Zanubrutinib for treating chronic lymphocytic leukaemia (TA931)
Evidence-based recommendations on zanubrutinib (Brukinsa) for treating chronic lymphocytic leukaemia in adults.
Transient loss of consciousness ('blackouts') in over 16s (CG109)
This guideline covers assessment, diagnosis and referral for people over 16 who have had a transient loss of consciousness (TLoC; also called a blackout). It aims to improve care for people with TLoC by specifying the most effective assessments and recommending when to refer to a specialist.
This guideline covers identifying and treating primary hypertension (high blood pressure) in people aged 18 and over, including people with type 2 diabetes. It aims to reduce the risk of cardiovascular problems such as heart attacks and strokes by helping healthcare professionals to diagnose hypertension accurately and treat it effectively.
NICE’s methods and processes for evaluating new treatments for use in the NHS are appropriate for the new class of Alzheimer’s drugs but key issues need to be considered, a new report has found.
NICE draft updated guideline recommends more treatment choices for menopause symptoms
New evidence shows that cognitive behavioural therapy (CBT) can help reduce menopause symptoms including hot flushes and night sweats, depressive symptoms and problems sleeping NICE has said in its draft updated guideline on menopause published today (17 November 2023).
Find health, social care and public health evidence and best practice resources.
NICE priority methodological research areas.
This guideline covers assessment of people aged 16 and over with symptoms and signs of acute respiratory infection (bacterial or viral) at first remote or in-person contact with NHS services. It also covers the initial management of any infections. It aims to support healthcare practitioners in making sure that people’s treatment follows the best care pathway. It forms part of a suite of work on virtual wards being undertaken by NICE.
Page 1 of 19 Taking a medicine to reduce the chance of developing breast cancer Decision aid for postmenopausal women at moderately increased
Page 1 of 11 Taking tamoxifen to reduce the chance of developing breast cancer Decision aid for premenopausal women at moderately increased risk
Page 1 of 11 Taking tamoxifen to reduce the chance of developing breast cancer Decision aid for premenopausal women at high risk Published
Page 1 of 19 Taking a medicine to reduce the chance of developing breast cancer Decision aid for postmenopausal women at high risk Published
NICE's quick guide on recognising and preventing delirium
Support for voluntary and community sector organisations using NICE guidance
Early value assessment (EVA) guidance on virtual reality technologies for treating agoraphobia or agoraphobic avoidance....
View recommendations for HTE15Show all sections
Extracorporeal carbon dioxide removal for acute respiratory failure (IPG776)
Evidence-based recommendations on extracorporeal carbon dioxide removal for acute respiratory failure. This involves taking blood out of the circulatory system and passing it across a synthetic membrane that allows some of the carbon dioxide in the blood to be removed. The blood is then returned to the circulatory system.
View recommendations for IPG776Show all sections
Evidence-based recommendations on lutetium-177 vipivotide tetraxetan (Pluvicto) for treating prostate-specific membrane antigen-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments in adults.
Biodegradable subacromial spacer insertion for rotator cuff tears (IPG775)
Evidence-based recommendations on biodegradable subacromial spacer insertion for rotator cuff tears. This involves inserting a balloon-shaped device between the top of the shoulder blade and the upper arm bone to reduce pain and improve shoulder function.
View recommendations for IPG775Show all sections
NICE is committed to supporting the national agenda for achieving a sustainable health and care system.
This guideline covers care for people with a family history of breast, ovarian or another related (prostate or pancreatic) cancer. It aims to improve the long-term health of these families by describing strategies to reduce the risk of and promote early detection of breast cancer (including genetic testing and mammography). It also includes advice on treatments (tamoxifen, raloxifene) and surgery (mastectomy).
Recommendation ID NG122/01 Question What is the effectiveness and cost effectiveness of immunotherapy in people with stage IIIA-N2 non‑small‑cell
Flow transcranial direct current stimulation for treating depression (MIB324)
NICE has developed a medtech innovation briefing (MIB) on Flow transcranial direct current stimulation for treating depression .
Biographies and interests register for the indicator advisory committee
NICE recommends life changing technology is rolled out to people with type 1 diabetes
Thousands of people with type 1 diabetes could be offered wearable technology to help them manage their condition following the publication of final draft guidance by NICE.
NICE launches refreshed support service for life sciences industry
NICE has launched its refreshed support service for the life sciences sector, NICE Advice.
Our board has 2 sub-committees: the audit and risk committee and the remuneration committee . Audit and risk committee The audit and risk committee
Angela sets out to understand some of the challenges, benefits and considerations of setting up and running a virtual ward, from the perspective of teams on the front lines.
A joint NICE and NHS England meeting can help to ensure you're ready for NHS patient access and subsequent NICE appraisal
Antimicrobial resistance (AMR) is an urgent global challenge. It causes around 700,000 deaths each year globally . That number is predicted to rise to
Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine, in adults.
Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic heart failure with preserved or mildly reduced ejection fraction in adults.
This guideline was developed before the COVID-19 pandemic. It covers diagnosing and managing pneumonia in adults who do not have COVID-19. It aims to improve accurate assessment and diagnosis of pneumonia to help guide antibiotic prescribing and ensure that people receive the right treatment.
This guideline covers diagnosing and treating jaundice, which is caused by increased levels of bilirubin in the blood, in newborn babies (neonates). It aims to help detect or prevent very high levels of bilirubin, which can be harmful if not treated.
NICE launches first modular update to its methods and processes
NICE’s methods and processes now include a proportionate approach to technology appraisals, and a new way of updating recommendations on COVID-19 treatments.
This guide describes the methods and processes, including expected timescales, that NICE follows when carrying out health technology evaluations. The methods and processes are designed to produce robust guidance for the NHS in an open, transparent and timely way, with appropriate contribution from stakeholders. Organisations invited to contribute to health technology evaluation development should read this manual in conjunction with the NICE health technology evaluation topic selection: the manual. All documents are available on the NICE website.
This quality standard covers the initial assessment and management of suspected acute respiratory infection in over 16s, including acute respiratory infection virtual wards.
View quality statements for QS210Show all sections
Sections for QS210
- Quality statements
- Quality statement 1: Documented initial assessment
- Quality statement 2: Prescribing antimicrobials
- Quality statement 3: Antibiotic duration
- Quality statement 4: Information about acute respiratory infection virtual wards
- Quality statement 5: Multidisciplinary team
- Quality statement 6: Support to self-manage on a virtual ward
- Quality statement 7: Virtual ward discharge summaries
The proportion of women aged 50-70 years whose record shows a breast screening test has been performed within the last 3 years Subject(s):
The percentage of patients on the learning disability register, who: received a learning disability health check and had a completed health action...
The percentage of urgent suspected colorectal cancer referrals accompanied by a faecal immunochemical test (FIT) result, with the result recorded in...
The percentage of patients on the learning disability register who received a learning disability health check and had a completed health action plan...
The proportion of invasive cases of cancer diagnosed via an emergency route
The proportion of invasive cases of cancer diagnosed via an emergency route Subject(s): Cancer
The proportion of eligible people aged 60-74 years whose record shows a bowel screening test has been performed within the last 2.5 years
First NICE-recommended treatment for Parkinson's set to benefit hundreds
Around 900 adults with advanced Parkinson’s are set to benefit from new treatment foslevodopa–foscarbidopa after NICE approved it for NHS use in final draft guidance published today (26 October 2023).
Evidence-based recommendations on ranibizumab (Lucentis) for treating diabetic macular oedema in adults.
View recommendations for TA274Show all sections
Evidence standards framework (ESF) for digital health technologies
NICE standards for innovators of digital health technologies and NHS commissioners
Evidence-based recommendations on daratumumab (Darzalex) with lenalidomide and dexamethasone for untreated multiple myeloma in adults, when a stem cell transplant is unsuitable.
Evidence-based recommendations on tirzepatide (Mounjaro) for type 2 diabetes in adults.